Procept BioRobotics stock maintains buy rating at Truist on utilization trends
Investing.com
Published Jun 18, 2025 11:01AM ET
Truist Securities maintained its buy rating and $70.00 price target on Procept BioRobotics Corp (NASDAQ:PRCT) Wednesday, citing positive utilization momentum and a strong capital pipeline. Currently trading at $60.07, the stock sits below analysts' price targets ranging from $60 to $90, with InvestingPro data showing impressive revenue growth of 59% over the last twelve months.
The research firm noted that management is taking a conservative approach to guidance early in the year, despite seeing healthy utilization momentum from March carrying over into April and May. This conservative stance potentially leaves room for upside to current expectations. According to InvestingPro 's analysis, the company maintains a strong financial health score, with liquid assets significantly exceeding short-term obligations.
Truist highlighted management's increasing confidence in the predictability of capital conversions, aided by more integrated delivery network (IDN) placements. The firm also emphasized the company's strong pipeline of capital equipment leads.
According to Truist, Procept's handpiece guidance continues to position the company for potential beat-and-raise scenarios throughout the year. Management deliberately exercised restraint in raising guidance following first-quarter handpiece upside.
The decision to maintain conservative guidance early in the year aligns with the company's approach of setting achievable targets that could be exceeded as utilization trends continue to develop positively, Truist noted.
In other recent news, Procept BioRobotics Corp reported its first-quarter 2025 earnings, exceeding analysts' expectations. The company posted earnings per share of -$0.45, surpassing the forecasted -$0.4907, and achieved revenue of $69.2 million, which outperformed the anticipated $65.43 million. This marks a significant year-over-year revenue growth of 55%, driven by a 50% increase in U.S. revenue. Leerink Partners subsequently adjusted Procept BioRobotics' price target to $90, down from $91, but maintained an Outperform rating. The firm noted a favorable risk/reward scenario, highlighting the company’s growth potential and upcoming catalysts in prostate cancer treatment. Procept BioRobotics also announced plans to expand its international presence, particularly in the UK and Japan. Additionally, the company's guidance for 2025 includes the distribution of 52,500 handpieces and a projected full-year revenue of $323 million, reflecting a 44% increase year-over-year. The company continues to focus on the untapped market for benign prostatic hyperplasia (BPH), leveraging its innovative technology for growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.